Pooled Analysis Continues to Show Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Patients with Advanced NSCLC Whose Tumors Do Not Express PD-L1

Findings from Pooled Analysis of KEYNOTE-189, KEYNOTE-407 and KEYNOTE-021 Presented at the IASLC 2019 World Conference on Lung Cancer